An approach to evaluating and comparing biomarkers for patient treatment selection
From MaRDI portal
Publication:6632697
DOI10.1515/IJB-2012-0052MaRDI QIDQ6632697
[[Person:6079254|Author name not available (Why is that?)]], Marshall D. Brown, Ying Huang, Margaret S. Pepe
Publication date: 5 November 2024
Published in: The International Journal of Biostatistics (Search for Journal in Brave)
Cites Work
- Title not available (Why is that?)
- Title not available (Why is that?)
- Performance guarantees for individualized treatment rules
- Analysis of randomized comparative clinical trial data for personalized treatment selections
- Evaluating Markers for Selecting a Patient's Treatment
- A Generalized Estimator of the Attributable Benefit of an Optimal Treatment Regime
- Logistic disease incidence models and case-control studies
- Assessing Treatment‐Selection Markers using a Potential Outcomes Framework
- Testing for Qualitative Interactions between Treatment Effects and Patient Subsets
- A Robust Method for Estimating Optimal Treatment Regimes
- Evaluating the Predictiveness of a Continuous Marker
- Patterns of treatment effects in subsets of patients in clinical trials
- False Discovery Rate–Adjusted Multiple Confidence Intervals for Selected Parameters
- Statistics for Weighing Benefits and Harms in a Proposed Genetic Substudy of a Randomized Cancer Prevention Trial
- Measures to summarize and compare the predictive capacity of markers
Related Items (1)
This page was built for publication: An approach to evaluating and comparing biomarkers for patient treatment selection
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q6632697)
